Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Introduction. In the absence of an HLA-identical sibling or a matched unrelated donor, whether to prefer a Haploidentical (Haplo) or a one antigen mismatched unrelated donor (MMUD) for allogeneic hematopoietic cell transplantation (HCT) remains an unanswered question. Implementation of graft-versus-...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2020-11, Vol.136 (Supplement 1), p.26-27
Main Authors: Battipaglia, Giorgia, Galimard, Jacques-Emmanuel, Labopin, Myriam, Angelucci, Emanuele, Blaise, Didier, Ruggeri, Annalisa, Gulbas, Zafer, Díez-Martín, José Luis, Koc, Yener, Castagna, Luca, Vitek, Antonin, Sica, Simona, Bruno, Benedetto, Moiseev, Ivan S., Rovira, Montserrat, Martino, Massimo, Araujo, Mercedes Colorado, Arat, Mutlu, Grillo, Giovanni, Martin, Hans, Corral, Lucía López, Pane, Fabrizio, Ciceri, Fabio, Nagler, Arnon, Mohty, Mohamad
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. In the absence of an HLA-identical sibling or a matched unrelated donor, whether to prefer a Haploidentical (Haplo) or a one antigen mismatched unrelated donor (MMUD) for allogeneic hematopoietic cell transplantation (HCT) remains an unanswered question. Implementation of graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCY) was initially pioneered in the Haplo and then also extended to MMUD setting, resulting in low rates of GVHD. Methods. This was a retrospective study from the EBMT registry. Included were adults undergoing either Haplo- or MMUD-HCT for acute myeloid leukemia during the period 2010-2018 and who were in first or second complete remission at allo-HCT. Only patients receiving unmanipulated grafts with PTCY as GVHD prophylaxis were included. Ex vivo and in vivo T-cell depletion were exclusion criteria. Comparisons were made among three groups: MMUD-HCT with peripheral blood as stem cell source (PBSC; n=124); Haplo-HCT with bone marrow (Haplo-BM; n=560); Haplo-HCT with PBSC (Haplo-PB; n=769). Results. Patients in Haplo-PB were older (median age of 55 years versus (vs) 52 and 51 years in MMUD-HCT and Haplo-BM, respectively; p
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2020-137099